These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 29427149)
1. Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors. Robison NJ; Yeo KK; Berliner AP; Malvar J; Sheard MA; Margol AS; Seeger RC; Rushing T; Finlay JL; Sposto R; Dhall G J Neurooncol; 2018 May; 138(1):199-207. PubMed ID: 29427149 [TBL] [Abstract][Full Text] [Related]
2. Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study. Le Teuff G; Castaneda-Heredia A; Dufour C; Jaspan T; Calmon R; Devos A; McHugh K; Leblond P; Frappaz D; Aerts I; Zwaan CM; Ducassou S; Chastagner P; Verschuur A; Corradini N; Casanova M; Rubie H; Riccardi R; Le Deley MC; Vassal G; Geoerger B; Pediatr Blood Cancer; 2020 Jan; 67(1):e28032. PubMed ID: 31595663 [TBL] [Abstract][Full Text] [Related]
3. A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation. Metts JL; Trucco M; Weiser DA; Thompson P; Sandler E; Smith T; Crimella J; Sansil S; Thapa R; Fridley BL; Llosa N; Badgett T; Gorlick R; Reed D; Gill J Cancer Med; 2023 Feb; 12(4):4270-4281. PubMed ID: 36151773 [TBL] [Abstract][Full Text] [Related]
4. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783 [TBL] [Abstract][Full Text] [Related]
5. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study. Hummel TR; Wagner L; Ahern C; Fouladi M; Reid JM; McGovern RM; Ames MM; Gilbertson RJ; Horton T; Ingle AM; Weigel B; Blaney SM Pediatr Blood Cancer; 2013 Sep; 60(9):1452-7. PubMed ID: 23554030 [TBL] [Abstract][Full Text] [Related]
6. Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018. Warren KE; Goldman S; Pollack IF; Fangusaro J; Schaiquevich P; Stewart CF; Wallace D; Blaney SM; Packer R; Macdonald T; Jakacki R; Boyett JM; Kun LE J Clin Oncol; 2011 Jan; 29(3):324-9. PubMed ID: 21149652 [TBL] [Abstract][Full Text] [Related]
7. A phase 1 study of entinostat in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1513, Pediatric Early Phase-Clinical Trial Network (PEP-CTN). Bukowinski A; Chang B; Reid JM; Liu X; Minard CG; Trepel JB; Lee MJ; Fox E; Weigel BJ Pediatr Blood Cancer; 2021 Apr; 68(4):e28892. PubMed ID: 33438318 [TBL] [Abstract][Full Text] [Related]
8. Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report. Berg SL; Cairo MS; Russell H; Ayello J; Ingle AM; Lau H; Chen N; Adamson PC; Blaney SM J Clin Oncol; 2011 Jan; 29(3):316-23. PubMed ID: 21149673 [TBL] [Abstract][Full Text] [Related]
9. Phase 1 study of pomalidomide in children with recurrent, refractory, and progressive central nervous system tumors: A Pediatric Brain Tumor Consortium trial. Fangusaro J; Mitchell DA; Kocak M; Robinson GW; Baxter PA; Hwang EI; Huang J; Onar-Thomas A; Dunkel IJ; Fouladi M; Warren KE Pediatr Blood Cancer; 2021 Feb; 68(2):e28756. PubMed ID: 33025730 [TBL] [Abstract][Full Text] [Related]
10. Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study. Lulla RR; Goldman S; Yamada T; Beattie CW; Bressler L; Pacini M; Pollack IF; Fisher PG; Packer RJ; Dunkel IJ; Dhall G; Wu S; Onar A; Boyett JM; Fouladi M Neuro Oncol; 2016 Sep; 18(9):1319-25. PubMed ID: 27022131 [TBL] [Abstract][Full Text] [Related]
11. Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411). Schafer ES; Rau RE; Berg SL; Liu X; Minard CG; Bishop AJR; Romero JC; Hicks MJ; Nelson MD; Voss S; Reid JM; Fox E; Weigel BJ; Blaney SM Pediatr Blood Cancer; 2020 Feb; 67(2):e28073. PubMed ID: 31724813 [TBL] [Abstract][Full Text] [Related]
12. A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors. Kieran MW; Chi S; Goldman S; Onar-Thomas A; Poussaint TY; Vajapeyam S; Fahey F; Wu S; Turner DC; Stewart CF; Moses M; Packer RJ; Jakacki R; Banerjee A; Boyett JM; Fouladi M; Kun L Childs Nerv Syst; 2015 Sep; 31(9):1433-45. PubMed ID: 26188774 [TBL] [Abstract][Full Text] [Related]
13. Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report. Leary SES; Park JR; Reid JM; Ralya AT; Baruchel S; Wu B; Roberts TPL; Liu X; Minard CG; Fox E; Weigel B; Blaney S Clin Cancer Res; 2017 Oct; 23(20):6062-6069. PubMed ID: 28751444 [No Abstract] [Full Text] [Related]
14. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Nicholson HS; Kretschmar CS; Krailo M; Bernstein M; Kadota R; Fort D; Friedman H; Harris MB; Tedeschi-Blok N; Mazewski C; Sato J; Reaman GH Cancer; 2007 Oct; 110(7):1542-50. PubMed ID: 17705175 [TBL] [Abstract][Full Text] [Related]
15. A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. Fine HA; Kim L; Albert PS; Duic JP; Ma H; Zhang W; Tohnya T; Figg WD; Royce C Clin Cancer Res; 2007 Dec; 13(23):7101-6. PubMed ID: 18056189 [TBL] [Abstract][Full Text] [Related]
16. A phase I study of irinotecan and temozolomide with bevacizumab in children with recurrent/refractory central nervous system tumors. Metts J; Harrington B; Salman E; Bradfield SM; Flanary J; Mosha M; Amankwah E; Stapleton S Childs Nerv Syst; 2022 May; 38(5):919-928. PubMed ID: 35260913 [TBL] [Abstract][Full Text] [Related]
17. A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study. Kilburn LB; Kocak M; Decker RL; Wetmore C; Chintagumpala M; Su J; Goldman S; Banerjee A; Gilbertson R; Fouladi M; Kun L; Boyett JM; Blaney SM Neuro Oncol; 2015 Feb; 17(2):303-11. PubMed ID: 25431212 [TBL] [Abstract][Full Text] [Related]
18. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. Korones DN; Benita-Weiss M; Coyle TE; Mechtler L; Bushunow P; Evans B; Reardon DA; Quinn JA; Friedman H Cancer; 2003 Apr; 97(8):1963-8. PubMed ID: 12673724 [TBL] [Abstract][Full Text] [Related]
19. Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma. Broniscer A; Jia S; Mandrell B; Hamideh D; Huang J; Onar-Thomas A; Gajjar A; Raimondi SC; Tatevossian RG; Stewart CF Pediatr Blood Cancer; 2018 Jul; 65(7):e27035. PubMed ID: 29512900 [TBL] [Abstract][Full Text] [Related]
20. A phase I study of irinotecan in combination with metronomic temozolomide in patients with recurrent glioblastoma. Reynés G; Balañá C; Gallego O; Iglesias L; Pérez P; García JL Anticancer Drugs; 2014 Jul; 25(6):717-22. PubMed ID: 24322542 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]